Forty Leading Organizations, Including 11 of the 20 Largest Dairy Companies in the World, Among First to Support New Global “Pathways to Dairy Net Zero” Climate Initiative
Pathways to Dairy Net Zero, a ground-breaking new climate initiative, is launching today during Climate Week and just prior to the United Nations (UN) Food Systems Summit. Forty leading organizations, including 11 of the 20 largest dairy companies in the world, have already declared their support for the effort. Collectively, these supporters represent approximately 30 percent of total milk production worldwide.
The new climate initiative demonstrates the global dairy sector’s commitment to reducing GHG emissions while continuing to produce nutritious foods for six billion people and provide for the livelihoods of one billion people.
“Pathways to Dairy Net Zero will accelerate climate efforts already underway and drive further necessary action to reduce dairy’s emissions over the next decades. The dairy sector has a lot to offer to lead this transition,” said Hein Schumacher, Chief Executive Officer of Royal FrieslandCampina and Chairman of Global Dairy Platform.
“Mengniu is proud to join the global dairy sector in uniting behind this effort, the first of its kind in agriculture, because we must all do our part to meet this worldwide climate challenge,” said Minfang (Jeffrey) Lu, Chief Executive Officer and Executive Director of China Mengniu Dairy Company.
The initiative is underpinned by six key principles:
- Mitigation. Continuing to improve production and process efficiency to further reduce the GHG emissions intensity of milk and dairy products.
- Greenhouse gas removals. Enhancing production practices that protect carbon sinks (soil, forests, grass, peatlands) and complement natural ecosystems.
- Avoidance and adaptation. Improving practices such as feed, manure, fertilizer and energy management.
- Insets and offsets. Identify and implement alternative, credible reduction options.
- Measurement and monitoring. Measuring greenhouse gas emissions to plan mitigation and monitor progress.
- Overall support. Promoting the global initiative and emphasizing the dairy sector’s climate ambition.
Identifying and Clarifying Plausible Mitigation Options
A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop science-based methodologies, tools and pathways that work for every dairy system.
Research is underway to identify where positive climate change action is possible. The study is led by Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre, research institutions from two of the Global Research Alliance on Agricultural Greenhouse Gases’ 65 member countries, backed up by data and analysis from the UN Food and Agriculture Organization.
Initial research found that the dairy sector already has the means to reduce a significant proportion of emissions - up to 40 percent in some systems - by improving productivity and resource use efficiency.1
Researchers are identifying plausible GHG mitigation pathways for different dairy systems globally, in particular methane reduction. The latest Intergovernmental Panel on Climate Change (IPCC) report2 reaffirmed that the main GHG challenge is the reduction of carbon dioxide, which remains in the atmosphere for centuries. The report also identified reductions in methane, a potent but short-lived climate pollutant that lasts only about 12 years in the atmosphere, as an immediate opportunity to address global warming.
Organizations Already Supporting Pathways to Dairy Net Zero
The list so far includes: Nestle, Dairy Farmers of America, Danone, Fonterra Co-operative Group, Royal FrieslandCampina, Arla Foods, China Mengniu Dairy Company, Saputo, Meiji Holdings, Savencia Fromage & Dairy, Agropur Dairy Cooperative, Ace Farming Company, Agri Networking Tools, Australian Dairy Products Federation, Brazzale, Dairy Australia, Dairy Connect, Dairy Farmers of Canada, Dairy Management Inc., Dairy UK, Dutch Dairy Association, First Milk, FOSS Analytics, Glanbia, Granja Tepeyac, Innovation Center for U.S. Dairy, International Dairy Foods Association, La Vida Lactea, Land O’Lakes, Lekhanath Dairy International, Leprino Foods Company, Livestock Improvement Corporation, Megmilk Snow Brand, Morinaga Milk Industry, National Dairy Development Board (India), National Milk Producers Federation (U.S.), Palmhouse Dairies, Pioneer Natural Capital, Royal DSM, U.S. Dairy Export Council.
For more information, or to join Pathways to Dairy Net Zero, visit: www.pathwaystodairynetzero.org.
About Pathways to Dairy Net Zero
Pathways to Dairy Net Zero is a vibrant, growing movement, the first of its kind in the world. It brings together dairy systems of every size and type, including organizations throughout the dairy supply chain.
Partners include: Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network.
The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.
References
- Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
- IPCC, 2021: Climate Change 2021: The Physical Science Basis. Contribution of Working Group I to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change [Masson-Delmotte, V., P. Zhai, A. Pirani, S. L. Connors, C. Péan, S. Berger, N. Caud, Y. Chen, L. Goldfarb, M. I. Gomis, M. Huang, K. Leitzell, E. Lonnoy, J. B. R. Matthews, T. K. Maycock, T. Waterfield, O. Yelekçi, R. Yu and B. Zhou (eds.)]. Cambridge University Press. In Press.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005358/en/
Contact information
Kevin Burkum, Director of Communications
+1 847-627-3387
Kevin.Burkum@GlobalDairyPlatform.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
